Key points are not available for this paper at this time.
The current study was carried out to find out the potential beneficial effects of Lcarnitine (LC) and allicin (ALC) to ameliorate the potential toxic effects of doxorubicin on kidneys.For this purpose, a total of 49 rats were divided in 7 groups (7/each) including a control group, a group treated with ALC (20mg/kg, orally), a group treated with DOX (20mg/kg.intraperitoneal injection), a group receiving ALC and DOX combination, a group receiving LC (100mg/kg/day), a group receiving ALC and DOX combination, and a group receiving ALC, DOX and LC in combination.The DOX induced an increase in creatinine and urea, however a significant decrease in total protein and albumin level was observed along with notable renal tissue damage.In terms of stress and oxidative parameters, DOX led to elevated TNF- expression, increase in MDA (malondialdehyde), decrease in reduced GSH (glutathione), SOD (superoxide dismutase) and CAT (catalase) levels.However, both ALC and LC, separately or in combination, effectively reduced kidney damage and apoptosis induced by DOX.Hence it is concluded that ALC and/or LC may be beneficial supplements for cancer patients undergoing DOX treatment.
A Wed, study studied this question.